Hedge fund manager defends IPR petitions
igor.stevanovic / Shutterstock.com
Acorda Therapeutics, the first company to be targeted through an inter partes review (IPR) filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office (USPTO) to reject the petition.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Acorda Therapeutics, inter partes review, USPTO, PTAB, patents